Adicet Bio, Inc. Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent
Adicet Bio, Inc. (ACET) reported Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent of $0 for the 12-month period ending 2022-12-31, per its 10-K filed 2023-03-15.
Discontinued › Income Statement
us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent · last filed 2023-03-15
- Adicet Bio, Inc. other comprehensive income (loss), net of tax, portion attributable to parent for fiscal 2022 was $0.00.
- Adicet Bio, Inc. other comprehensive income (loss), net of tax, portion attributable to parent for fiscal 2019 was $90.00K.
- Adicet Bio, Inc. other comprehensive income (loss), net of tax, portion attributable to parent for fiscal 2018 was -$41.00K.
| Period end | Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent 12 month |
|---|---|
| 2022-12-31 | $0.00 10-K · filed 2023-03-15 |
| 2019-12-31 | $90.00K 10-K · filed 2020-03-12 |
| 2018-12-31 | -$41.00K 10-K · filed 2020-03-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Valion Bio, Inc. (VBIO) | United States | $0.077B | |
| Lifevantage Corp (LFVN) | United States | $0.078B | 15.40 |
| MAIA Biotechnology, Inc. (MAIA) | United States | $0.077B | -2.30 |
| iBio, Inc. (IBIO) | United States | $0.077B | -2.94 |
| Verrica Pharmaceuticals Inc. (VRCA) | United States | $0.076B | -3.39 |
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |
| Gain Therapeutics, Inc. (GANX) | United States | $0.080B | -4.40 |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |